AVEO Oncology announces FDA acceptance for filing of an NDA for Tivozanib as treatment of relapsed or refractory renal cell carcinoma
The FDA has assigned the application standard review and a Prescription Drug User Fee Act target action date of March 31, 2021. The FDA also indicated that they